Logo image of IMA

IMAGENEBIO INC (IMA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IMA - US45175G2075 - Common Stock

6.21 USD
-0.49 (-7.31%)
Last: 12/2/2025, 8:00:02 PM
6.25 USD
+0.04 (+0.64%)
After Hours: 12/2/2025, 8:00:02 PM
Fundamental Rating

3

Overall IMA gets a fundamental rating of 3 out of 10. We evaluated IMA against 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for IMA as it has an excellent financial health rating, but there are worries on the profitability. IMA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IMA has reported negative net income.
IMA had a negative operating cash flow in the past year.
In the past 5 years IMA always reported negative net income.
In the past 5 years IMA always reported negative operating cash flow.
IMA Yearly Net Income VS EBIT VS OCF VS FCFIMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M -80M

1.2 Ratios

IMA has a Return On Assets (-34.79%) which is in line with its industry peers.
IMA's Return On Equity of -39.10% is in line compared to the rest of the industry. IMA outperforms 56.77% of its industry peers.
Industry RankSector Rank
ROA -34.79%
ROE -39.1%
ROIC N/A
ROA(3y)-36.73%
ROA(5y)-30.05%
ROE(3y)-42.01%
ROE(5y)-36.93%
ROIC(3y)N/A
ROIC(5y)N/A
IMA Yearly ROA, ROE, ROICIMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMA Yearly Profit, Operating, Gross MarginsIMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

8

2. Health

2.1 Basic Checks

IMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMA has about the same amout of shares outstanding than it did 1 year ago.
IMA has less shares outstanding than it did 5 years ago.
There is no outstanding debt for IMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMA Yearly Shares OutstandingIMA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IMA Yearly Total Debt VS Total AssetsIMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -0.89, we must say that IMA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IMA (-0.89) is comparable to the rest of the industry.
IMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.89
ROIC/WACCN/A
WACC9.05%
IMA Yearly LT Debt VS Equity VS FCFIMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 11.80 indicates that IMA has no problem at all paying its short term obligations.
With an excellent Current ratio value of 11.80, IMA belongs to the best of the industry, outperforming 80.73% of the companies in the same industry.
IMA has a Quick Ratio of 11.80. This indicates that IMA is financially healthy and has no problem in meeting its short term obligations.
IMA has a Quick ratio of 11.80. This is amongst the best in the industry. IMA outperforms 80.73% of its industry peers.
Industry RankSector Rank
Current Ratio 11.8
Quick Ratio 11.8
IMA Yearly Current Assets VS Current LiabilitesIMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for IMA have decreased strongly by -20.81% in the last year.
The Revenue for IMA has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-20.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.48%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

IMA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.60% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.48%
EPS Next 2Y26.69%
EPS Next 3Y8.35%
EPS Next 5Y9.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMA Yearly Revenue VS EstimatesIMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2030 2031 2032 50M 100M 150M 200M
IMA Yearly EPS VS EstimatesIMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMA Price Earnings VS Forward Price EarningsIMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMA Per share dataIMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.69%
EPS Next 3Y8.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMAGENEBIO INC

NASDAQ:IMA (12/2/2025, 8:00:02 PM)

After market: 6.25 +0.04 (+0.64%)

6.21

-0.49 (-7.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners29.88%
Inst Owner ChangeN/A
Ins Owners3.7%
Ins Owner Change9.42%
Market Cap69.43M
Revenue(TTM)N/A
Net Income(TTM)-49.23M
Analysts80
Price Target281.52 (4433.33%)
Short Float %4.06%
Short Ratio5.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.51%
Min EPS beat(2)0.99%
Max EPS beat(2)22.03%
EPS beat(4)4
Avg EPS beat(4)16.01%
Min EPS beat(4)0.99%
Max EPS beat(4)22.03%
EPS beat(8)7
Avg EPS beat(8)11.1%
EPS beat(12)9
Avg EPS beat(12)6.9%
EPS beat(16)12
Avg EPS beat(16)-3.92%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB 0.55
EV/EBITDA N/A
EPS(TTM)-8.07
EYN/A
EPS(NY)-3.35
Fwd EYN/A
FCF(TTM)-4.11
FCFYN/A
OCF(TTM)-4.11
OCFYN/A
SpS0
BVpS11.26
TBVpS11.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -34.79%
ROE -39.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.73%
ROA(5y)-30.05%
ROE(3y)-42.01%
ROE(5y)-36.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.8
Quick Ratio 11.8
Altman-Z -0.89
F-Score3
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.48%
EPS Next Y31.48%
EPS Next 2Y26.69%
EPS Next 3Y8.35%
EPS Next 5Y9.6%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-66.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.31%
OCF growth 3YN/A
OCF growth 5YN/A

IMAGENEBIO INC / IMA FAQ

Can you provide the ChartMill fundamental rating for IMAGENEBIO INC?

ChartMill assigns a fundamental rating of 3 / 10 to IMA.


What is the valuation status of IMAGENEBIO INC (IMA) stock?

ChartMill assigns a valuation rating of 0 / 10 to IMAGENEBIO INC (IMA). This can be considered as Overvalued.


How profitable is IMAGENEBIO INC (IMA) stock?

IMAGENEBIO INC (IMA) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for IMA stock?

The Earnings per Share (EPS) of IMAGENEBIO INC (IMA) is expected to grow by 31.48% in the next year.